CO2023018650A2 - Formulaciones de anticuerpo anti-tgf-beta y su uso - Google Patents

Formulaciones de anticuerpo anti-tgf-beta y su uso

Info

Publication number
CO2023018650A2
CO2023018650A2 CONC2023/0018650A CO2023018650A CO2023018650A2 CO 2023018650 A2 CO2023018650 A2 CO 2023018650A2 CO 2023018650 A CO2023018650 A CO 2023018650A CO 2023018650 A2 CO2023018650 A2 CO 2023018650A2
Authority
CO
Colombia
Prior art keywords
tgf
antibody formulations
beta antibody
beta
formulations
Prior art date
Application number
CONC2023/0018650A
Other languages
English (en)
Inventor
Kiran Rana Bangari
Ramil Latypov
Timothy Mccoy
Sanket Patke
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CO2023018650A2 publication Critical patent/CO2023018650A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación proporciona composiciones farmacéuticas que comprenden anticuerpos anti-TGF-β.
CONC2023/0018650A 2021-06-18 2023-12-29 Formulaciones de anticuerpo anti-tgf-beta y su uso CO2023018650A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163212473P 2021-06-18 2021-06-18
PCT/US2022/034103 WO2022266510A1 (en) 2021-06-18 2022-06-17 Anti-tgf-beta antibody formulations and their use

Publications (1)

Publication Number Publication Date
CO2023018650A2 true CO2023018650A2 (es) 2024-01-15

Family

ID=82656620

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0018650A CO2023018650A2 (es) 2021-06-18 2023-12-29 Formulaciones de anticuerpo anti-tgf-beta y su uso

Country Status (11)

Country Link
US (1) US20230036928A1 (es)
EP (1) EP4355363A1 (es)
KR (1) KR20240022608A (es)
CN (1) CN117915948A (es)
AU (1) AU2022294100A1 (es)
BR (1) BR112023026404A2 (es)
CA (1) CA3224018A1 (es)
CO (1) CO2023018650A2 (es)
IL (1) IL309310A (es)
TW (1) TW202317185A (es)
WO (1) WO2022266510A1 (es)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060286105A1 (en) 2003-04-30 2006-12-21 Steven Ledbetter Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
CA2607448C (en) * 2005-04-22 2014-11-18 Eli Lilly And Company Tgf beta 1 specific antibodies
EP2173163A4 (en) * 2007-07-06 2010-12-08 Glaxosmithkline Llc ANTIBODY FORMULATIONS
RU2625034C2 (ru) 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Антитела и другие молекулы, которые связывают в7-н1 и pd-1
ES2792183T3 (es) 2013-09-13 2020-11-10 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
BR112017021688A2 (pt) * 2015-04-17 2018-08-14 Bristol-Myers Squibb Company composições compreendendo uma combinação de um anticorpo anti-pd-1 e outro anticorpo
TW202313678A (zh) 2017-01-20 2023-04-01 法商賽諾菲公司 抗TGF-β抗體及其用途
JP2021531254A (ja) * 2018-07-11 2021-11-18 スカラー ロック インコーポレイテッドScholar Rock, Inc. 高親和性のアイソフォーム選択的ＴＧＦβ１阻害剤、およびその使用
WO2020014473A1 (en) * 2018-07-11 2020-01-16 Scholar Rock, Inc. TGFβ1 INHIBITORS AND USE THEREOF
EP3849513A1 (en) * 2018-09-11 2021-07-21 Ichnos Sciences SA Compositions comprising a bispecific antibody, bufffer and one or more stabilizing agents

Also Published As

Publication number Publication date
KR20240022608A (ko) 2024-02-20
AU2022294100A1 (en) 2024-02-01
IL309310A (en) 2024-02-01
CA3224018A1 (en) 2022-12-22
CN117915948A (zh) 2024-04-19
EP4355363A1 (en) 2024-04-24
US20230036928A1 (en) 2023-02-02
TW202317185A (zh) 2023-05-01
BR112023026404A2 (pt) 2024-03-05
WO2022266510A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
CO2020010303A2 (es) Conjugados de il-15, y sus usos
CO2018008754A2 (es) Composición farmacéutica que comprende constructos de anticuerpo biespecíficos
CL2018003520A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco.
CR20180154A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
UY36889A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CL2021003580A1 (es) Compuestos que comprenden un ligando de proteína de activación de fibroblastos y su uso
AR054474A1 (es) Formulacion de anticuerpos estables
CL2022000087A1 (es) Anticuerpo anti-tau y uso del mismo
CO6630181A2 (es) Composiciones y métodos para uso de anticuerpos terapéuticos de lrp6( proteina relacionada con lipoproteínas de baja densidad 6)
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
BR112021004316A2 (pt) Anticorpos de agonistas anti-trem-2
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
CO2019008675A2 (es) Anticuerpos anti-lag3 radiomarcados para la obtención de imágenes mediante inmuno-pet
CO2021010697A2 (es) Formulación de anticuerpos terapéuticos
AR119997A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
CL2020003391A1 (es) Proteína de unión al antígeno anti-steap1
CL2023002797A1 (es) Formulaciones y composiciones farmacéuticas que comprenden una proteína de unión a antígeno enmascarada
JOP20210015A1 (ar) تركيبات مضادات fcrn وطرق استخدامها
CO2022009691A2 (es) Formulaciones líquidas de tasimelteón y métodos para su uso
AR122930A1 (es) Anticuerpos de pre-direccionamiento y métodos de uso
CO2023018650A2 (es) Formulaciones de anticuerpo anti-tgf-beta y su uso
CO2019013718A2 (es) Anticuerpos anti-trkb
CO2023000505A2 (es) Anticuerpos anti-notch2 y métodos de uso
CL2022001486A1 (es) Formulaciones de anticuerpos anti-pd-l1.
BR112023002984A2 (pt) Formulações de anticorpo terapêutico